Colorectal cancer care disparities in an urban diverse population: A tale of two hospitals in the nation’s capital.
Identifying Fit-for-Emulation Data: Adaptation of a Structured Data Feasibility Assessment Process for Real-World Oncology Trial Emulations
P2-06-22: PreciseBreast, an AI-enabled digital test predicting breast cancer recurrence is equivalent with Oncotype in an observational, retrospective study of patients from Baptist Health Miami Cancer Institute in partnership with COTA, Inc.
Trends in All-Cause Mortality Rates in Patients with Follicular Lymphoma in the US before and during the COVID-19 Pandemic: A Retrospective Observational Study
An Indirect Comparison of Elranatamab’s Progression-Free Survival, Duration of Response, and Overall Survival from MagnetisMM-3 Versus Real-World External Control Arms in Triple-Class Refractory Multiple Myeloma
Impact of the Diagnosis-to-Treatment Interval (DTI) on Outcomes in Older Adults with Diffuse Large B-Cell Lymphoma (DLBCL) Treated in the Real-World Setting
End-of-Life Care Patterns in Older Patients with Diffuse Large B-Cell Lymphoma (DLBCL) in the Real-World Setting
P3-03-20: A multicenter retrospective review of clinical-pathological characteristics associated with survival outcomes in a large cohort of metaplastic breast cancer patients
656P Real-World (RW) frontline (1L) treatments (Txs) in patients (Pts) with advanced non-small-cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EFGR) exon 20 insertions (exon20ins) and adjusted comparisons versus PAPILLON study
1346P A population-level prognostic score model for early acquired resistance to frontline anti-PD-(L)1 therapy in metastatic non-small cell lung cancer (NSCLC)
